mcw casino video
NoneTechnology has arguably been Wall Street's hottest sector in 2024. Rapid growth in emerging industries, such as artificial intelligence (AI), has fueled a massive rally, making this year one of the best for technology stocks in recent memory. Now, it's time to turn the page to 2025. After doing some homework, three Motley Fool contributors identified Broadcom ( AVGO 24.43% ) , Qualcomm ( QCOM 0.18% ) , and Meta Platforms ( META -1.65% ) as stocks poised to win big in 2025 and beyond. All three stocks have a history of big-time investment returns, so you may already know them. But try not to overthink it; winners often continue to have success. Below is the pitch for why each should continue delivering fantastic returns for your portfolio. Broadcom closed out 2024 with a bang, setting the table for more gains Justin Pope (Broadcom): It's hard not to like Broadcom heading into 2025, even after the stock has galloped over 95% higher since January. The semiconductor and enterprise software company recently closed out its fiscal year 2024, a banner year that signals strong business momentum heading into next year. Broadcom's fiscal year 2024 revenue totaled $51.5 billion, a 44% increase over 2023. The company built its name on semiconductors, but Broadcom has expanded into enterprise software, including infrastructure and security. It acquired VMware for $69 billion late last year, and the incremental revenue helped Broadcom grow its software business by 181% in 2024. The company's revenue is now split roughly 60-40 between semiconductors and software. Semiconductor revenue exceeded $30 billion in 2024 but grew just 7% from last year. However, artificial intelligence has become an increasingly exciting growth opportunity. Broadcom began working with prominent AI developer OpenAI earlier this year, and recent reports indicate that Broadcom is developing a dedicated AI chip for Apple 's data center servers. It sets the table for big things ahead. These are early-stage opportunities for Broadcom, which grew its AI revenue by 220% in 2024 to $12.1 billion. The AI-driven hyper-growth Nvidia has enjoyed seems to be beginning to show up in Broadcom's business. That bodes well for the stock, which trades at 29 times 2025 earnings estimates. This is a solid buying level for a company that analysts estimate will compound earnings at a 20% growth rate over the long term. Broadcom was a star in 2024, and its strong business results and developing AI opportunities could continue rewarding investors in 2025 and beyond. Diversification may be the key to this stock's recovery Will Healy (Qualcomm): Qualcomm stock does not look like a winning stock at first glance. It has struggled since the summer as its 5G-driven growth runs its course. Moreover, Apple plans to launch a competing smartphone chipset in 2027, likely ending its relationship with Qualcomm. Such a move would probably reduce the benefits it would experience from an AI upgrade cycle. In fiscal 2024, its handset segment, which houses the smartphone chipset business, comprised 64% of company revenues, meaning the loss of Apple's business affects its largest revenue source. However, Qualcomm has long prepared for the day when its chipsets are less in demand. To that end, it has diversified into IoT and automotive, and its car-related segment has experienced particular success. Although its overall revenue grew by only 9% in fiscal 2024 (ended Sept. 29), automotive revenue grew by 55%. Additionally, Qualcomm released PC chips earlier this year. Its Snapdragon X Elite chips are faster than Apple's M2 chip in some respects. Also, assuming the rumors that it wants to acquire some or all of Intel are true, its influence in the chip industry could grow if such a buyout occurs. Despite these concerns, the semiconductor stock is up by 20% over the last year, even after dropping more than 30% from its June high. That decline has taken Qualcomm's P/E ratio to 18, far below its chip industry competitors. Admittedly, Qualcomm's path is somewhat uncertain as it prepares for a likely loss of Apple's business and invests more heavily in new market niches. Still, as it builds on its growth in automotive, PCs, and other businesses, investors may want to buy some Qualcomm shares while its earnings multiple is still low. Meta is a market-beating stock that investors shouldn't overlook Jake Lerch (Meta Platforms): Meta has been a market-beating stock for some time now. Since its debut as a public company back in 2012, Meta's shares have generated a compound annual growth rate (CAGR) of 24.8%. That's nearly twice the return of the S&P 500 , which has generated a CAGR of 15.2% over the same period. More to the point, Meta's outperformance has been even more evident recently. As of this writing, Meta stock is up 75% year-to-date, as opposed to a 28% year-to-date return for the S&P 500. However, it's not just Meta's track record that should make it appealing to investors as we head into 2025. What I love about the stock is its cash-generating power. Over the last 12 months, Meta generated $156 billion in revenue, making it the 22nd largest American company by revenue (having just passed Home Depot earlier this year). But what truly catches my eye is how much free cash flow Meta generates. Over the last 12 months, Meta has tallied more than $52 billion in free cash flow. Simply put, Meta is a high-margin business that has a river of cash to return value to shareholders in any number of ways, including r epurchasing shares, p aying down debt, making s trategic acquisitions, and/or p aying out dividends. Indeed, Meta announced a $50 billion share buyback plan back in February, along with a first-ever quarterly dividend. Investors who are looking for a market-beating stock for the long term should consider Meta.
The Legislative Council football team won against the Hong Kong Association of Freight Forwarding and Logistics Football Team by 3-1 during a friendly yesterday. The match took place at the Hammer Hill Road Sports Ground in Diamond Hill at 2pm. A total of seven legislators, including the football team leader, Steven Ho Chun-yin from the Democratic Alliance for the Betterment and Progress of Hong Kong, Aron Kwok Wai-keung from the labor sector, Ma Fung-kwok from the election committee sector, Perry Yiu Pak-leung for the tourism constituency, Tik Chi-yuen from the social welfare constituency and Scott Leung Man-kwong, teamed up to beat the association. The one-and-only female player at the match was the election committee lawmaker Doreen Kong Yuk-foon, who joined about 10 minutes into the match, while Technology and Innovation constituency lawmaker Duncan Chiu Tat-kun also participated as a reserve player. After the match, Kong told reporters that it was her first soccer competition and that she enjoyed it.HUNTINGTON BEACH, Calif. , Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems , is pleased to announce the appointment of Ayman Mohamed as its new Chief Technology Officer, effective November 18 , signaling a new direction in innovation and technology leadership. With over 20 years of senior leadership, strategic, and operational product management experience, Ayman brings a wealth of knowledge and expertise to the role. Ayman Mohamed is a seasoned technology leader with a proven track record of launching innovative products in new and existing markets, generating significant revenue streams, and creating profitable enterprises. His passion for building high-quality products and commitment to servant leadership have earned him a reputation for building trust and fostering collaborative, high-performing teams. Throughout his career, Ayman has demonstrated a deep understanding of software architecture and broad hands-on technical skills. He has successfully helped organizations succeed, with experience spanning startups and larger companies in the San Francisco Bay and Washington DC metro areas. In his new role at Beacon Healthcare Systems, Ayman will lead engineering and delivery teams, develop a product roadmap, and lead technology development, testing, and implementation efforts. "We are thrilled to have Ayman join Beacon Healthcare Systems at this pivotal time. Our vision is to harness cutting-edge technologies to enhance our products, implementations, and continue to give our clients the level of quality they expect," said Todd Petersen , CEO. Ayman Mohamed's previous roles include leadership positions at Amazon Web Services, American Well, Avizia, Intersections Inc, Zumetrics, Moasis Global, and Ultra Zoom Technologies. His strategic and operational skills, combined with his ability to thrive in dynamic environments and his bias for action, make him an invaluable asset to Beacon Healthcare Systems. About Beacon Healthcare Systems. Beacon Healthcare Systems streamlines the business of healthcare through reliable innovative SaaS technology delivered by industry experts. With a focus on appeals and grievances, compliance, and analytics, Beacon HCS is the first place health plans turn when looking for a trusted, experienced partner that can help them reduce costs, grow revenue, and achieve their strategic goals. Founded in 2011, Beacon HCS is a privately held California -based company. Visit our website at www.beaconhcs.com Media Contact: 9048744189 | Dkroog@ beacon@beaconhcs.com View original content to download multimedia: https://www.prnewswire.com/news-releases/beacon-healthcare-systems-expands-leadership-team-with-addition-of-ayman-mohamed-as-chief-technology-officer-302313686.html SOURCE Beacon Healthcare Systems Best trending stories from the week. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. You may occasionally receive promotions exclusive discounted subscription offers from the Roswell Daily Record. Feel free to cancel any time via the unsubscribe link in the newsletter you received. You can also control your newsletter options via your user dashboard by signing in.
CHICAGO (AP) — N.J. Benson had 22 points and 17 rebounds in DePaul's 84-65 victory over Loyola Maryland on Saturday. Benson added 17 rebounds for the Blue Demons (9-4). Jacob Meyer added 12 points while shooting 4 for 11 (0 for 3 from 3-point range) and 4 of 4 from the free-throw line while they also had five rebounds. CJ Gunn went 4 of 11 from the field (1 for 5 from 3-point range) to finish with 11 points. The Greyhounds (5-6) were led in scoring by Jacob Theodosiou, who finished with 22 points. Milos Ilic added 13 points, six rebounds and two steals for Loyola (MD). Jordan Stiemke had 10 points. DePaul took the lead with 18:45 left in the first half and did not relinquish it. Benson led their team in scoring with 14 points in the first half to help put them up 44-26 at the break. DePaul extended its lead to 64-36 during the second half, fueled by an 8-0 scoring run. Isaiah Rivera scored a team-high 10 points in the second half as his team closed out the win. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
Canucks lines vs Kraken, December 28, 2024Angara inherits problem left by Sara at DepEd
Mangaluru: Featherlite unveils new experience centre showcasing office, education furniture rangeInside Liam Payne's poignant funeral - Cheryl's large role, Bear's tribute and Kate Cassidy meeting his parents
Signing with Dodgers was really easy decision for 2-time Cy Young winner Blake SnellFACT FOCUS: Vermont ruling does not say schools can vaccinate children without parental consent
Social media users are misrepresenting a Vermont Supreme Court ruling , claiming that it gives schools permission to vaccinate children even if their parents do not consent. The ruling addressed a lawsuit filed by Dario and Shujen Politella against Windham Southeast School District and state officials over the mistaken vaccination of their child against COVID-19 in 2021, when he was 6 years old. A lower court had dismissed the original complaint, as well as an amended version. An appeal to the U.S. Supreme Court was filed on Nov. 19. But the ruling by Vermont's high court is not as far-reaching as some online have claimed. In reality, it concluded that anyone protected under the Public Readiness and Emergency Preparedness Act, or PREP, Act is immune to state lawsuits. Here's a closer look at the facts. CLAIM: The Vermont Supreme Court ruled that schools can vaccinate children against their parents' wishes. THE FACTS: The claim stems from a July 26 ruling by the Vermont Supreme Court, which found that anyone protected by the PREP Act is immune to state lawsuits, including the officials named in the Politella's suit. The ruling does not authorize schools to vaccinate children at their discretion. According to the lawsuit, the Politella's son — referred to as L.P. — was given one dose of the Pfizer BioNTech COVID-19 vaccine at a vaccination clinic held at Academy School in Brattleboro even though his father, Dario, told the school's assistant principal a few days before that his son was not to receive a vaccination. In what officials described as a mistake, L.P. was removed from class and had a “handwritten label” put on his shirt with the name and date of birth of another student, L.K., who had already been vaccinated that day. L.P. was then vaccinated. Ultimately, the Vermont Supreme Court ruled that officials involved in the case could not be sued. “We conclude that the PREP Act immunizes every defendant in this case and this fact alone is enough to dismiss the case,” the Vermont Supreme Court's ruling reads. “We conclude that when the federal PREP Act immunizes a defendant, the PREP Act bars all state-law claims against that defendant as a matter of law.” The PREP Act , enacted by Congress in 2005, authorizes the secretary of the Department of Health and Human Services to issue a declaration in the event of a public health emergency providing immunity from liability for activities related to medical countermeasures, such as the administration of a vaccine, except in cases of “willful misconduct" that result in “death or serious physical injury.” A declaration against COVID-19 was issued on March 17, 2020. It is set to expire on Dec. 31. Federals suits claiming willful misconduct are filed in Washington. Social media users described the Vermont Supreme Court's ruling as having consequences beyond what it actually says. “The Vermont Supreme Court has ruled that schools can force-vaccinate children for Covid against the wishes of their parents,” reads one X post that had been liked and shared approximately 16,600 times as of Tuesday. “The high court ruled on a case involving a 6-year-old boy who was forced to take a Covid mRNA injection by his school. However, his family had explicitly stated that they didn't want their child to receive the ‘vaccines.’” Other users alleged that the ruling gives schools permission to give students any vaccine without parental consent, not just ones for COVID-19. Rod Smolla, president of the Vermont Law and Graduate School and an expert on constitutional law, told The Associated Press that the ruling “merely holds that the federal statute at issue, the PREP Act, preempts state lawsuits in cases in which officials mistakenly administer a vaccination without consent.” “Nothing in the Vermont Supreme Court opinion states that school officials can vaccinate a child against the instructions of the parent,” he wrote in an email. Asked whether the claims spreading online have any merit, Ronald Ferrara, an attorney representing the Politellas, told the AP that although the ruling doesn't say schools can vaccinate students regardless of parental consent, officials could interpret it to mean that they could get away with doing so under the PREP Act, at least when it comes to COVID-19 vaccines. He explained that the U.S. Supreme Court appeal seeks to clarify whether the Vermont Supreme Court interpreted the PREP Act beyond what Congress intended. “The Politella’s fundamental liberty interest to decide whether their son should receive elective medical treatment was denied by agents of the State and School,” he wrote in an email to the AP. “The Vermont Court misconstrues the scope of PREP Act immunity (which is conditioned upon informed consent for medical treatments unapproved by FDA), to cover this denial of rights and its underlying battery.” Ferrara added that he was not aware of the claims spreading online, but that he “can understand how lay people may conflate the court's mistaken grant of immunity for misconduct as tantamount to blessing such misconduct.” John Klar, who also represents the Politellas, went a step further, telling the AP that the Vermont Supreme Court ruling means that “as a matter of law” schools can get away with vaccinating students without parental consent and that parents can only sue on the federal level if death or serious bodily injury results. — Find AP Fact Checks here: https://apnews.com/APFactCheck .
PC Wizard relocates, opens shop on Main Street
After maths, CBSE to bring 2-tier system for science, social science40cr devotees to visit Maha Kumbh but govt making preps for 100 cr: Yogi
They say man and dog have a unique bond, unbreakable in fact – could this bond be reiterated in the form of a tablet that can increase the lifespan of both species effectively? Scientists think so. A San Francisco based bio-technology organisation has unleashed plans to study the relationship between human life and dog life, with active testing in the works to see if a longevity enacting drug made for dogs can have similar impacts on us. Loyal potential Loy-002, a compound and accessible pill for dogs, is reported to launch in the market as soon as early 2025, with grand promises of slowing and even reversing metabolic changes associated with aging in dogs. The substance aims to reduce frailty by suppressing specific age driven increases in insulin, thus reducing the risk of disease, promoting better all-round health. Most Read on Euro Weekly News ‘Living nostradamus’ gives cryptic predictions for 2025 Scientists discover 'giant' worms hidden below the seafloor Astro-photographer captures cosmic grinch! With many similarities between man and dog in regard to environmental habits, compared with common controls in most clinical trials, mice, for instance, the results of studies into the promise of this drug truly could spell a great potential for human health in the future. Loyal founder, Celine Halioua, is supremely optimistic. Major investment into testing “Finding out how to prevent canine age-related decline is a really strong proxy for doing the same with humans because dogs get similar age-related diseases. Lab mice cannot be justly compared as dogs can”. And with over $125 million raised from keen investors already, with much of the appeal of the drug coming from the fast-track method of testing due to shorter dog lifespans, as opposed to human trials, it’s clear to see the traction Loyal is generating. FDA to approve alternative drug by Dog Aging Project The concept of dog longevity testing is not solely limited to Loyal’s efforts however, as Rapamycin is currently undergoing clinical approval, with FDA supposedly set to give the all-clear depending on the outcome of intensive studies conducted by the Dog Aging Project. Researchers of the campaign, organised at the laboratories in the University of Washington, are brimming with excitement to see how positive effects on dogs could correlate in humans, considering Rapamycin is already a regularly used human immunosuppressant. The co-founder of the project, UW biogerontologist Daniel Promislow told the Guardian: “Our study is light years ahead of anything that’s been done on humans, or can be done on humans”. Studies conducted will amass the equivalent of a forty year long trial on humans, in just five years, concluding ultimately if the key to enhancing our health can be found in canine supplementation. Jamie Justice, professor of Gerontology and Geriatric Medicine at Wake Forest University School of Medicine offered a valuable, conservative insight: “The Dog Aging Project is still five years away from releasing any results, and thus at this time researchers cannot test canine longevity drugs on humans, no matter how positive results are on dogs”. Follow all the latest health news across Europe here on Euro Weekly News.
Foreign-born CEO says Japan needs immigration